The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.

abstract：:Survival alone is no longer an adequate outcome for persons with brain tumors; the quality of the survivorship experience should be viewed with equal importance. Symptom management is a significant component of quality survivorship care. Regardless of their histology, brain tumors and therapies used to treat them prod...

journal_title：Neuro-oncology

authors： Amidei C

更新日期：2018-11-09 00:00:00

abstract：BACKGROUND:The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but t...

journal_title：Neuro-oncology

authors： de la Fuente MI,Young RJ,Rubel J,Rosenblum M,Tisnado J,Briggs S,Arevalo-Perez J,Cross JR,Campos C,Straley K,Zhu D,Dong C,Thomas A,Omuro AA,Nolan CP,Pentsova E,Kaley TJ,Oh JH,Noeske R,Maher E,Choi C,Gutin PH,Ho

更新日期：2016-02-01 00:00:00

abstract：Background:Molecular profile of glioblastoma multiforme (GBM) revealed 4 subtypes, 2 of which, proneural and mesenchymal, have been predominantly observed, with the latter displaying a more aggressive phenotype and increased therapeutic resistance. Single-cell RNA sequencing revealed that multiple subtypes actually res...

journal_title：Neuro-oncology

authors： Teng J,da Hora CC,Kantar RS,Nakano I,Wakimoto H,Batchelor TT,Chiocca EA,Badr CE,Tannous BA

更新日期：2017-06-01 00:00:00

abstract：:The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal. Understanding the potential behavior of these tumors in individual patients is critical for rational therapeuti...

journal_title：Neuro-oncology

authors： Pérez-Magán E,Rodríguez de Lope A,Ribalta T,Ruano Y,Campos-Martín Y,Pérez-Bautista G,García JF,García-Claver A,Fiaño C,Hernández-Moneo JL,Mollejo M,Meléndez B

更新日期：2010-12-01 00:00:00

abstract：Background:Depending on the level, differentiation state, and tumor stage, reactive nitrogen and oxygen species inhibit or increase cancer growth and tumor initiating cell maintenance. The rate-limiting enzyme in a pathway that can regulate reactive species production but has not been thoroughly investigated in gliobla...

journal_title：Neuro-oncology

authors： Tran AN,Walker K,Harrison DG,Chen W,Mobley J,Hocevar L,Hackney JR,Sedaka RS,Pollock JS,Goldberg MS,Hambardzumyan D,Cooper SJ,Gillespie Y,Hjelmeland AB

更新日期：2018-07-05 00:00:00

abstract：:Medulloblastomas are the most common malignant tumors of the central nervous system during childhood. Radiation-induced medulloblastoma tumor recurrences are aggressive and metastatic in nature. In the present study, we demonstrate that Gadd45a expression can sensitize medulloblastoma cells to radiotherapy. We have el...

journal_title：Neuro-oncology

authors： Asuthkar S,Nalla AK,Gondi CS,Dinh DH,Gujrati M,Mohanam S,Rao JS

更新日期：2011-10-01 00:00:00

abstract：Background:Malignant glioma (MG) is a devastating neuro-oncologic disease with almost invariably poor prognosis. Prognostic awareness (PA) is the awareness of incurable disease and shortened life expectancy (LE). Accurate PA is associated with favorable psychological outcomes at the end of life (EoL) for patients with ...

journal_title：Neuro-oncology

authors： Diamond EL,Prigerson HG,Correa DC,Reiner A,Panageas K,Kryza-Lacombe M,Buthorn J,Neil EC,Miller AM,DeAngelis LM,Applebaum AJ

更新日期：2017-10-19 00:00:00

abstract：:The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intrav...

journal_title：Neuro-oncology

authors： Bradley KA,Pollack IF,Reid JM,Adamson PC,Ames MM,Vezina G,Blaney S,Ivy P,Zhou T,Krailo M,Reaman G,Mehta MP,Children's Oncology Group.

更新日期：2008-10-01 00:00:00

abstract：BACKGROUND:Recent molecular characterization studies have identified clinically relevant molecular subtypes to coexist within the same histological entities of glioma. Comparative studies between serum-supplemented and serum-free (SF) culture conditions have demonstrated that SF conditions select for glioma stem-like c...

journal_title：Neuro-oncology

authors： Balvers RK,Kleijn A,Kloezeman JJ,French PJ,Kremer A,van den Bent MJ,Dirven CM,Leenstra S,Lamfers ML

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Previous pilot studies have shown the feasibility of preoperative chemotherapy in patients with medulloblastoma, but benefits and risks compared with initial surgery have not been assessed. METHODS:Two therapeutic strategies were retrospectively compared in 92 patients with metastatic medulloblastoma treate...

journal_title：Neuro-oncology

authors： Guerrini-Rousseau L,Abbas R,Huybrechts S,Kieffer-Renaux V,Puget S,Andreiuolo F,Beccaria K,Blauwblomme T,Bolle S,Dhermain F,Longaud Valès A,Roujeau T,Sainte-Rose C,Tauziede-Espariat A,Varlet P,Zerah M,Valteau-Couanet D,D

更新日期：2020-11-26 00:00:00

abstract：:We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogen...

journal_title：Neuro-oncology

authors： Perrone F,Da Riva L,Orsenigo M,Losa M,Jocollè G,Millefanti C,Pastore E,Gronchi A,Pierotti MA,Pilotti S

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:The influence of survivin isoforms on outcome in glioblastoma is poorly understood. We analyzed the dominant anti-apoptotic transcript variants of survivin using expression data and modeled them in vivo to determine their impact on glioma formation and progression. METHODS:Using data from low- and high-grad...

journal_title：Neuro-oncology

authors： Doucette T,Latha K,Yang Y,Fuller GN,Rao A,Rao G

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized that BM are not evenly distributed ac...

journal_title：Neuro-oncology

authors： Yanagihara TK,McFaline-Figueroa JR,Giacalone NJ,Lee AW,Soni V,Hwang ME,Hsieh KT,Saraf A,Wu CC,Yang D,Wen PY,Ashamalla H,Aizer AA,Wang TJC,Huang RY

更新日期：2019-05-06 00:00:00

abstract：:To determine the effectiveness of stereotactic radiosurgery (SRS) treatment to central nervous system (CNS) hemangioblastomas in von Hippel-Lindau disease (VHL), we analyzed long-term results in VHL patients treated with SRS. Patients were enrolled in a prospective VHL natural history study, undergoing SRS treatment o...

journal_title：Neuro-oncology

authors： Asthagiri AR,Mehta GU,Zach L,Li X,Butman JA,Camphausen KA,Lonser RR

更新日期：2010-01-01 00:00:00

abstract：:Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity. A total of 44 patients with glioblastoma with gros...

journal_title：Neuro-oncology

authors： Ulmer S,Spalek K,Nabavi A,Schultka S,Mehdorn HM,Kesari S,Dörner L

更新日期：2012-04-01 00:00:00

abstract：:Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...

journal_title：Neuro-oncology

authors： Hottinger AF,Pacheco P,Stupp R

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma. METHODS:Patients 22 years of age or less with recurrent ependymoma were treated with bolus dosage 5-FU weekly fo...

journal_title：Neuro-oncology

authors： Wright KD,Daryani VM,Turner DC,Onar-Thomas A,Boulos N,Orr BA,Gilbertson RJ,Stewart CF,Gajjar A

更新日期：2015-12-01 00:00:00

abstract：:Protein kinase C alpha (PKC-alpha) is a cytoplasmic serine threonine kinase involved in regulating cell differentiation and proliferation. Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice. In this ...

journal_title：Neuro-oncology

authors： Grossman SA,Alavi JB,Supko JG,Carson KA,Priet R,Dorr FA,Grundy JS,Holmlund JT

更新日期：2005-01-01 00:00:00

abstract：INTRODUCTION:Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid...

journal_title：Neuro-oncology

authors： Alimova I,Birks DK,Harris PS,Knipstein JA,Venkataraman S,Marquez VE,Foreman NK,Vibhakar R

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:Diffuse intrinsic pontine gliomas (DIPGs) are highly lethal childhood brain tumors. Their unique genetic makeup, pathological heterogeneity, and brainstem location all present challenges to treatment. Developing mouse models that accurately reflect each of these distinct features will be critical to advance ...

journal_title：Neuro-oncology

authors： Patel SK,Hartley RM,Wei X,Furnish R,Escobar-Riquelme F,Bear H,Choi K,Fuller C,Phoenix TN

更新日期：2020-03-05 00:00:00

abstract：:Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular therapeutic strategies for GBM treatment. In this study, we profiled DNA copy number and mRNA expression in 21 independent GBM tumor lines maint...

journal_title：Neuro-oncology

authors： Hodgson JG,Yeh RF,Ray A,Wang NJ,Smirnov I,Yu M,Hariono S,Silber J,Feiler HS,Gray JW,Spellman PT,Vandenberg SR,Berger MS,James CD

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...

journal_title：Neuro-oncology

authors： de Blank PM,Berman JI,Liu GT,Roberts TP,Fisher MJ

更新日期：2013-08-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...

journal_title：Neuro-oncology

authors： Roth P,Weller M

更新日期：2014-10-01 00:00:00

abstract：:Survivorship has become a significant topic within oncologic care. The tools and means by which the provision of survivorship care can be implemented and delivered are in development and are the focus of significant research oncology-wide. These tools and methods include innovations of survivorship care delivery, surv...

journal_title：Neuro-oncology

authors： Leeper H,Milbury K

更新日期：2018-11-09 00:00:00

abstract：BACKGROUND:Mutations involving isocitrate dehydrogenase 1 (IDH 1) occur in a high proportion of diffuse gliomas, with implications on diagnosis and prognosis. About 90% involve exon 4 at codon 132, replacing amino acid arginine with histidine (R132H). Rarer ones include R132C, R132S, R132G, R132L, R132V, and R132P. Mos...

journal_title：Neuro-oncology

authors： Agarwal S,Sharma MC,Jha P,Pathak P,Suri V,Sarkar C,Chosdol K,Suri A,Kale SS,Mahapatra AK,Jha P

更新日期：2013-06-01 00:00:00

abstract：:The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas. Patients with stable or progressive malignant primar...

journal_title：Neuro-oncology

authors： Prados MD,Lamborn KR,Chang S,Burton E,Butowski N,Malec M,Kapadia A,Rabbitt J,Page MS,Fedoroff A,Xie D,Kelley SK

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Nonfunctioning pituitary adenoma (NFPA) and growth hormone pituitary adenoma (GHPA) are major subtypes of pituitary adenomas (PAs). The primary treatment is surgical resection. However, radical excision remains challenging, and few effective medical therapies are available. It is urgent to find novel targets...

journal_title：Neuro-oncology

authors： Shi C,Ye Z,Han J,Ye X,Lu W,Ji C,Li Z,Ma Z,Zhang Q,Zhang Y,He W,Chen Z,Cao X,Shou X,Zhou X,Wang Y,Zhang Z,Li Y,Ye H,He M,Chen H,Cheng H,Sun J,Cai J,Huang C,Ye F,Luo C,Zhou B,Ding H,Zhao Y

更新日期：2020-08-17 00:00:00

abstract：BACKGROUND:Malignant glioma is an aggressive cancer requiring new therapeutic targets. MicroRNAs (miRNAs) regulate gene expression post transcriptionally and are implicated in cancer development and progression. Deregulated expressions of several miRNAs, specifically hsa-miR-184, correlate with glioma development. MET...

journal_title：Neuro-oncology

authors： Emdad L,Janjic A,Alzubi MA,Hu B,Santhekadur PK,Menezes ME,Shen XN,Das SK,Sarkar D,Fisher PB

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...

journal_title：Neuro-oncology

authors： Boxerman JL,Zhang Z,Safriel Y,Larvie M,Snyder BS,Jain R,Chi TL,Sorensen AG,Gilbert MR,Barboriak DP

更新日期：2013-07-01 00:00:00

abstract：:Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates remain poor despite decades of clinical trials of conventional and novel, biologically targeted therapeutics. There is considerable evidence that most of these therapeutics do not reach their targets in the brain when administered...

journal_title：Neuro-oncology

authors： Vogelbaum MA,Aghi MK

更新日期：2015-03-01 00:00:00